Business

CollPlant's rhCollagen-Based BioInk Demonstrates Strong Performance Compared to Matrigel® in Study Conducted by Technion - Israel Institute of Technology

CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen), today announced positive results from a head-to-head comparative study of its rhCollagen-based bioink, Collink.3D™, and Matrigel®, conducted by the Levenberg Lab at Technion - Israel Institute of Technology.

articleCorning IncorporatedOctober 20, 20257/company/corning-incorporated/news/collplants-rhcollagen-based-bioink-demonstrates-strong-performance-compared-to-matrigelr-in-study-conducted-by-technion-israel-institute-of-technology
CollPlant's rhCollagen-Based BioInk Demonstrates Strong Performance Compared to Matrigel® in Study Conducted by Technion - Israel Institute of Technology

About this update from Corning Incorporated

[{"type":"list","items":[{"val":[{"type":"text","content":"A head-to-head study by Israel's Technion found that CollPlant's rhCollagen-based bioink, Collink.3D™, outperformed Matrigel®, a leading extracellular matrix, in supporting structured tissue formation.","length":209,"tagName":"p"}]},{"val":[{"type":"text","content":"The findings suggest Collink.3D™ could offer a consistent, tunable, and animal-free alternative for advanced tissue engineering and research applications.","length":154,"tagName":"p"}]},{"val":[{"type":"text","content":"Extracellular matrices are key tools in drug discovery, regenerative medicine, and tissue modeling. CollPlant's plant-based technology provides a sustainable and ethical approach without compromising performance.","length":216,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":579,"olType":false},{"type":"text","content":"REHOVOT, Israel, Oct. 20, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen), today announced positive results from a head-to-head comparative study of its rhCollagen-based bioink, Collink.3D™, and Matrigel®, conducted by the Levenberg Lab at Technion - Israel Institute of Technology.","length":456,"tagName":"p"},{"type":"image","alt":"Collink.3D (left image) exhibited skeletal Muscle elongation while Matrigel (right image) appeared non-uniform on day 7 (Technion)","displaySize":"","headline":null,"caption":"Collink.3D (left image) exhibited skeletal Muscle elongation while Matrigel (right image) appeared non-uniform on day 7 (Technion)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":196,"url":"https://media.zenfs.com/en/prnewswire.com/f6b78f41766e2115698eac1e909a1957"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/R71FgnqVxuKsF17S2bl9sg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTM0NTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/f6b78f41766e2115698eac1e909a1957","width":400,"height":196}},"href":"https://mma.prnewswire.com/media/2800257/CollPlant_Photo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Matrigel®, developed and marketed by Corning, has been one of the most widely used extracellular matrices for more than three decades. Derived from the...

More updates from Corning Incorporated

regenerative medicinetissue engineeringextracellular matrixaesthetic medicineTechnionCollPlantCollPlant Biotechnologiestissue formation3D bioprintingMatrigel